Top Suppliers:I want be here
Related CAS#:
97867-33-9 857213-31-1
86483-48-9 1130050-35-9
528851-30-1 105093-21-8
102-92-1 133210-96-5
85721-33-1 860033-22-3
1158522-08-7 940364-43-2
134104-43-1 131615-57-1
6906-52-1 930439-75-1
1018584-77-4 1375289-11-4
849349-65-1 127437-46-1

97867-33-9

97867-33-9 structure
97867-33-9 structure
  • Name: Ciprofloxacin Lactate Soluble
  • Chemical Name: 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid,2-hydroxypropanoic acid
  • CAS Number: 97867-33-9
  • Molecular Formula: C20H24FN3O6
  • Molecular Weight: 403.404
  • Catalog: API Synthetic anti-infective drugs Quinolone
  • Create Date: 2018-02-06 08:00:00
  • Modify Date: 2024-01-02 05:07:11
  • Ciprofloxacin (Bay-09867) lactate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin lactate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin lactate has anti-proliferative activity and induces apoptosis. Ciprofloxacin lactate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1][2][3][4].
Name 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid,2-hydroxypropanoic acid
Synonyms Flunase [inj.]
Cipobacter
Ciproflox [inj.]
Ciprobid Eye Drops
Ciproxin [inj.]
Flociprin [inj.]
Ciproxina [inj.]
Quintor Eye Drops
Ificipro
1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic 2-hydroxypropanoic anhydride
MFCD01759747
Description Ciprofloxacin (Bay-09867) lactate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin lactate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin lactate has anti-proliferative activity and induces apoptosis. Ciprofloxacin lactate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1][2][3][4].
Related Catalog
In Vitro Ciprofloxacin (Bay-09867) lactate (5-50 μg/mL; 0-24 h; tendon cells) inhibits cell proliferation and causes cell cycle arrest at the G2/M phase[1]. Ciprofloxacin (Bay-09867) lactate shows potent activity against Y. pestis and B. anthracis with MIC90 of 0.03 μg/mL and 0.12 μg/mL, respectively[2]. Cell Cycle Analysis[1] Cell Line: Tendon cells Concentration: 5, 10, 20 and 50 μg/mL Incubation Time: 24 hours Result: Decreased the cellularity of tendon cells. Apoptosis Analysis[1] Cell Line: Tendon cells Concentration: 50 μg/mL Incubation Time: 24 hours Result: Arrested cell cycle at the G2/M phase and inhibited cell division in tendon cells. Western Blot Analysis[1] Cell Line: Tendon cells Concentration: 50 μg/mL Incubation Time: 0, 6, 12, 17 and 24 hours Result: Down-regulated the expression of CDK-1 and cyclin B protein and mRNA. Up-regulated the expression of PLK-1 protein.
In Vivo Ciprofloxacin (Bay-09867) lactate (30 mg/kg; i.p.; for 24 hours; BALB/c mice) has protection against Y. pestis in murine model of pneumonic plague[3]. Ciprofloxacin (Bay-09867) lactate (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) accelerates aortic root enlargement and increases the incidence of aortic dissection and rupture by decreases LOX level and increases MMP levels and activity in the aortic wall[4]. Ciprofloxacin (Bay-09867) lactate (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) induces DNA damage and release of DNA to the cytosol, mitochondrial dysfunction, and activation of cytosolic DNA sensor signaling. Ciprofloxacin lactate increases apoptosis and necroptosis in the aortic wall[4]. Animal Model: BALB/c mice[3] Dosage: 30 mg/kg Administration: Intraperitoneal injection; for 24 hours Result: Reduced the lung bacterial load in murine model of pneumonic plague. Animal Model: C57BL/6J mice[4] Dosage: 100 mg/kg Administration: Oral gavage; daily, for 4 weeks Result: Had aortic destruction that was accompanied by decreased LOX expression and increased MMP expression and activity. Animal Model: C57BL/6J mice[4] Dosage: 100 mg/kg Administration: Oral gavage; daily, for 4 weeks Result: Caused mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased apoptosis and necroptosis in the aortic wall.
References

[1]. Tsai WC, et, al. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63.

[2]. Steenbergen J, et, al. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16.

[3]. Hamblin KA, et, al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.

[4]. LeMaire SA, et, al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804.
Density 1.4±0.1 g/cm3
Boiling Point 656.4±55.0 °C at 760 mmHg
Melting Point 255-257ºC
Molecular Formula C20H24FN3O6
Molecular Weight 403.404
Flash Point 350.8±31.5 °C
Exact Mass 403.154358
PSA 100.87000
LogP 0.04
Vapour Pressure 0.0±2.1 mmHg at 25°C
Index of Refraction 1.624
Hazard Codes Xi
HS Code 2933491000
HS Code 2933491000
Summary 2933491000. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:6.5%. General tariff:20.0%

Chemsrc provides CAS#:97867-33-9 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 97867-33-9 | Chemsrc address: https://m.chemsrc.com/en/baike/844710.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved